Last close As at 05/08/2026
GBP4.65
▲ −5.50 (−1.17%)
Market capitalisation
GBP5,792m
Research: Industrials
The announcement with GE further demonstrates the market-leading position of GKN Aerospace: technology and production capability to win original equipment (OE) work and repair and maintenance capability to win greater aftermarket work. Arguably the most important element for shareholders is the extension within the risk and revenue sharing partnerships (RRSPs), which demonstrates the importance of GKN Aerospace to GE’s overall engine offering while also providing greater exposure to the lucrative aero engine aftermarket.
Melrose Industries |
GE partnership expansion |
Contract award |
Aerospace and defence |
7 November 2023 |
Share price performance
Business description
Analyst
Melrose Industries is a research client of Edison Investment Research Limited |
|||||||||||||||||||||||||||||||||||
The announcement with GE further demonstrates the market-leading position of GKN Aerospace: technology and production capability to win original equipment (OE) work and repair and maintenance capability to win greater aftermarket work. Arguably the most important element for shareholders is the extension within the risk and revenue sharing partnerships (RRSPs), which demonstrates the importance of GKN Aerospace to GE’s overall engine offering while also providing greater exposure to the lucrative aero engine aftermarket.
Year end |
Revenue (£m) |
PBT* |
EPS* |
DPS |
P/E |
Yield |
12/22 |
2,957 |
62 |
4.1 |
2.3 |
124.0 |
0.4 |
12/23e |
3,410 |
288 |
16.8 |
4.2 |
30.3 |
0.8 |
12/24e |
3,605 |
415 |
24.9 |
6.3 |
20.4 |
1.2 |
12/25e |
4,068 |
616 |
37.5 |
9.4 |
13.6 |
1.8 |
Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.
Melrose has announced an expansion of its agreements with GE on the GEnx, CF6 and GE90 engines, which supply the wide body civil aircraft market, primarily Boeing 777/787 and Airbus A330. It is a combination of OE, additional aftermarket and greater involvement in the aftermarket RRSPs. OE work brings life-of-programme contracts to deliver 100% of GEnx, CF6 and GE90 fan cases, as well as 50% of GE9X fan case assembly. Key to winning the business are GKN Aerospace’s burgeoning capabilities in additive fabrication and manufacturing, as highlighted in our recent update note, offering significant manufacturing efficiencies, including lead times, and reduced carbon footprint, a committed goal for GE. GKN Aerospace will also join GE Aerospace’s aftermarket repair network, supporting GEnx with specialised repair content for complex structural components. This reflects GKN Aerospace’s recent investment in its aftermarket network, including a new facility in Malaysia and a major expansion of its US site, along with technology that additive fabrication brings to the repair of critical parts such as fan blades. Perhaps the most important element is the expansion of GKN Aerospace’s participation in the GEnx RRSPs, which will provide additional aftermarket revenues in return for the additional value created in the upstream (OE) element of the programme. This will expand and potentially elongate the cash profile of the RRSP portfolio, which is a significant contributor to the overall value within Melrose, 61% of Edison’s valuation in our initiation note.
The financial impact equates to c $5bn over the 30+ year lifetime – suggesting over $150m a year through full production. The additional business is expected to ramp-up over the next few years with the potential to add 6–7% to the Engines division or 2–3% to group revenue from 2026.
There is no impact to short-term financial expectations. The next scheduled trading update is on 16 November.
|
|
Research: Healthcare
Molecure has released its Q323 report, providing an update on its clinical development activities, particularly around its oral, first-in-class inhibitor, OATD-01. Following the acceptance of the Investigational New Drug (IND) application in July 2023, the Phase II proof-of-concept study (KITE) for OATD-01 in pulmonary sarcoidosis remains on track with the first US patient expected to receive dosing in Q423. Additionally, we anticipate the company to obtain approval to commence recruitment for the KITE study in Europe in Q124, as the application was submitted to the EMA and MHRA in September 2023. Recruitment for Molecure’s second clinical-stage asset, OATD-02, in patients with advanced and/or metastatic solid tumours, is ongoing, and we now anticipate initial data in early 2024 (previously expected in Q423). As of 30 September 2023, Molecure had a gross cash position of PLN85m, which includes the PLN50m (c $12m) from the Q323 public offering. However, to support its strategic plans for 2023–25, the company will need to seek additional funding to fully cover its estimated capital expenditure requirement of PLN250m.